US 12,071,516 B2
Polymeric stabilizing formulations
Ryan Olf, Emeryville, CA (US); Lyle Gordon, Emeryville, CA (US); and Wouter Roorda, Emeryville, CA (US)
Assigned to Nano Precision Medical, Inc., Alameda, CA (US)
Filed by Nano Precision Medical, Inc., Emeryville, CA (US)
Filed on Apr. 27, 2021, as Appl. No. 17/241,818.
Application 17/241,818 is a continuation in part of application No. PCT/US2021/019559, filed on Feb. 25, 2021.
Application 17/241,818 is a continuation in part of application No. 16/600,249, filed on Oct. 11, 2019, granted, now 11,021,576.
Application PCT/US2021/019559 is a continuation of application No. 15/508,572, granted, now 10,479,868, issued on Nov. 19, 2019, previously published as PCT/US2015/048677, filed on Sep. 4, 2015.
Claims priority of provisional application 62/983,296, filed on Feb. 28, 2020.
Claims priority of provisional application 62/045,834, filed on Sep. 4, 2014.
Prior Publication US 2021/0246271 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7088 (2006.01); A61K 9/00 (2006.01); A61K 31/541 (2006.01); A61K 38/26 (2006.01); A61K 47/60 (2017.01); C08G 83/00 (2006.01); A61K 38/02 (2006.01); A61K 38/20 (2006.01); A61K 38/22 (2006.01)
CPC C08G 83/003 (2013.01) [A61K 9/0024 (2013.01); A61K 31/541 (2013.01); A61K 38/26 (2013.01); A61K 47/60 (2017.08); A61K 38/02 (2013.01); A61K 38/208 (2013.01); A61K 38/22 (2013.01)] 20 Claims
 
1. A method for stabilizing a pharmaceutical composition in a capsule configured to be implanted, the method comprising:
providing a pharmaceutical composition comprising a therapeutic agent, which therapeutic agent is a peptide, together with a polymeric stabilizing agent comprising a polymer having a plurality of stabilizing groups, wherein the polymer is a dendritic polymer or is a cross-linked polymer;
providing a capsule having a reservoir and a nanoporous membrane with a plurality of pores, wherein said pharmaceutical composition is disposed within the reservoir, the capsule configured for implantation; and
the polymeric stabilizing agent having molecular dimensions larger than the pore size of the nanoporous membrane, wherein the release of the polymeric stabilizing agent from the reservoir is substantially prevented; and wherein the nanoporous membrane is a diffusion pathway out of the reservoir for the therapeutic agent.